Recombinant Human BACE1 Protein (Active) is a Human Fragment protein, in the 46 to 457 aa range, expressed in HEK 293, with >=95% purity and <= 0.005 EU/µg endotoxin level.
E T D E E P E E P G R R G S F V E M V D N L R G K S G Q G Y Y V E M T V G S P P Q T L N I L V D T G S S N F A V G A A P H P F L H R Y Y Q R Q L S S T Y R D L R K G V Y V P Y T Q G K W E G E L G T D L V S I P H G P N V T V R A N I A A I T E S D K F F I N G S N W E G I L G L A Y A E I A R P D D S L E P F F D S L V K Q T H V P N L F S L Q L C G A G F P L N Q S E V L A S V G G S M I I G G I D H S L Y T G S L W Y T P I R R E W Y Y E V I I V R V E I N G Q D L K M D C K E Y N Y D K S I V D S G T T N L R L P K K V F E A A V K S I K A A S S T E K F P D G F W L G E Q L V C W Q A G T T P W N I F P V I S L Y L M G E V T N Q S F R I T I L P Q Q Y L R P V E D V A T S Q D D C Y K F A I S Q S S T G T V M G A V I M E G F Y V V F D R A R K R I G F A V S A C H V H D E F R T A A V E G P F V T L D M E D C G Y N I P Q T D E S T L M T
Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase (PubMed:10656250, PubMed:10677483, PubMed:20354142). Cleaves CHL1 (By similarity).
BACE, KIAA1149, BACE1, Beta-secretase 1, Aspartyl protease 2, Beta-site amyloid precursor protein cleaving enzyme 1, Memapsin-2, Membrane-associated aspartic protease 2, ASP2, Asp 2, Beta-site APP cleaving enzyme 1
Recombinant Human BACE1 Protein (Active) is a Human Fragment protein, in the 46 to 457 aa range, expressed in HEK 293, with >=95% purity and <= 0.005 EU/µg endotoxin level.
pH: 7.4
Constituents: 10.26% Trehalose, 0.727% Dibasic monohydrogen potassium phosphate, 0.248% Potassium phosphate monobasic
Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase (PubMed:10656250, PubMed:10677483, PubMed:20354142). Cleaves CHL1 (By similarity).
Belongs to the peptidase A1 family.
N-Glycosylated (PubMed:11083922, PubMed:17425515). Addition of a bisecting N-acetylglucosamine by MGAT3 blocks lysosomal targeting, further degradation and is required for maintaining stability under stress conditions (By similarity).
This product is an active protein and may elicit a biological response in vivo, handle with caution.
BACE1 also known as beta-site APP cleaving enzyme 1 or beta-secretase plays an important role in the cleavage of amyloid precursor protein (APP). This cleavage results in the production of amyloid-beta peptides which are associated with Alzheimer's disease. BACE1 is a membrane-bound aspartic protease and has a molecular weight of approximately 50100 Da. The enzyme expresses mostly in the brain's neurons and some secretory tissues.
BACE1 initiates the amyloidogenic pathway of APP processing which involves amyloid-beta generation. BACE1 doesn't function alone but acts as part of a complex that aids in protein substrate recognition and processing. Its activity contributes to physiological processes like myelination and axonal guidance indicating its importance beyond amyloid production.
BACE1 is integral to the amyloidogenic pathway which is important in Alzheimer's disease development. It interacts with proteins such as presenilin 1 a part of the gamma-secretase complex that further processes the amyloid-beta precursor. Furthermore BACE1 links to synaptic functions and neural signaling pathways highlighting its multifaceted roles.
BACE1 holds significance in Alzheimer's disease due to its role in amyloid-beta peptide production. This connection has led to the development of BACE1 inhibitors as potential therapeutic agents. Additionally BACE1’s involvement in other neural functions ties it to cognitive impairments. It also relates to APP through its function in Alzheimer's suggesting targeted strategies for treatment could involve modulating BACE1 activity.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Fully biologically active determined by its ability to cleave fluorogenic peptide substrate MCA-SEVNLDAEFR-Lys(DNP)-RR-NH2. Specific activity is ≥ 4.2 pmol/min/ug.
SDS-PAGE analysis of ab290084
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com